Cell culture media play a crucial role in the field of gene therapy production, specifically tailored to support the growth, viability, and productivity of cells involved in manufacturing gene therapy products like viral vectors. These specialized media are distinct from general-purpose ones due to the stringent requirements for safety, yield, and regulatory compliance in gene therapy applications.
Fujifilm Biosciences has recently unveiled BalanCD HEK293 Perfusion A, a cutting-edge addition to their gene therapy application solutions. This medium, leveraging suspension HEK293 cells and perfusion technology, offers scalable production of viral vectors essential for gene therapy development. Erik Vaessen, the chief business officer at Fujifilm Biosciences, highlights the significance of this advancement in the realm of gene therapy.
HEK293 cells have long been recognized for their utility in gene therapy applications within upstream bioprocessing. Their attributes include reliable growth rates, high transfection success, and the expression of crucial cellular factors required for virus replication. BalanCD HEK293 Perfusion A takes this a step further by facilitating process optimization through enhanced cell growth, viability, and productivity, catering to various applications such as viral vector production, transient protein expression, and recombinant protein synthesis.
Engineered for high-density perfusion culture, BalanCD HEK293 Perfusion A comes in a range of media package options suitable for continuous processing. This medium is compatible with diverse transfection methods and supports both steady-state and intensified perfusion processes, making it a versatile choice for gene therapy production.
By harnessing the advantages of perfusion technology, BalanCD HEK293 Perfusion A contributes to a reduction in overall capital expenditures associated with the production of key virus types like AAV and LV, essential for gene transfer both in vivo and in vitro. This reduction in costs aligns with the goal of enhancing resource utilization for consistency, scalability, and the development of clinical-quality, high-performing media to support large-scale commercial batch sizes in advanced therapy development.
Key Takeaways:
– BalanCD HEK293 Perfusion A Medium from Fujifilm Biosciences offers enhanced gene therapy production capabilities through its specialized design for viral vector production.
– The medium is tailored for high-density perfusion culture and supports various applications, including transient protein expression and recombinant protein production.
– Leveraging perfusion technology, BalanCD HEK293 Perfusion A contributes to cost reduction and improved resource utilization in gene therapy production processes.
Tags: regulatory, upstream, cell culture, gene therapy, viral vectors, biotech
Read more on genengnews.com